


## Myopia Management Made Practical

Science, Candidacy, and Integration Into Daily Practice

By: Ariel Cerenzie, OD, FAAO, FSLs




## An Increasing Concern WORLDWIDE



Holden, et al. Ophthalmology. 2016

## An Increasing Concern UNITED STATES



Holden, et al. Ophthalmology. 2016

The Importance of  
Myopia Management

Myopia Management  
Treatment Options &  
Prescribing Guide


Risk Factors for  
Developing  
Myopia/High Myopia

Setting  
Your  
Price

## The Importance of Myopia Management

## PATHOPHYSIOLOGY

## Myopia PATHOPHYSIOLOGY



Cooper, Jeffrey, and Andrei V. Thachenko. 'A review of current concepts of the etiology and treatment of myopia.' *Eye & contact lens* 44.4 (2018): 231.

## CONSEQUENCES


## GLAUCOMA

## GLAUCOMA

## RISKS ASSOCIATED WITH MYOPIA


| LEVEL OF MYOPIA  | CATARACTS | GLAUCOMA | RETINAL DETACHMENT | MYOPIC MACULAR DEGENERATION |
|------------------|-----------|----------|--------------------|-----------------------------|
| -1.00 to -3.00 D | 2x        | 4x       | 3x                 | 2x                          |
| -3.00 to -6.00 D | 3x        | 4x       | 9x                 | 10x                         |
| Over -6.00 D     | 5x        | 14x      | 22x                | 41x                         |

Flitcroft, D. J. 'The complex interactions of retinal, optical and environmental factors in myopia aetiology.' *Progress in retinal and eye research* 31.6 (2012): 622-660.




For each unit (1-D) increase in myopia, the risk of glaucoma increases by approximately **20%**.

Ha, Abdul, et al. 'Degree of myopia and glaucoma risk: a dose-response meta-analysis.' *American Journal of Ophthalmology* (2021).  
Mitchell P, Hourihan F, Sandilich J, Wang JJ. The relationship between glaucoma and myopia: the Blue Mountains Eye Study. *Ophthalmology*. 1999;106(10):2010-2015.



Geyu R, Yang H, Han Y, Samuels BC, Sigal DA. Connective Tissue Remodeling in Myopia and Its Potential Role in Increasing Risk of Glaucoma. *Curr Opin Biomed Eng*. 2020;25:40-50. doi:10.1016/j.cobeng.2020.01.008




Park, Hae-Young, Leptidis, et al. "Vertical disc tilt and features of the optic nerve head anatomy are related to visual field defect in myopic eyes." Scientific reports 9:1 (2019): 1-9.

## RETINAL DETACHMENT

| LEVEL OF MYOPIA  | CATARACTS | GLAUCOMA | RETINAL DETACHMENT | MYOPIC MACULAR DEGENERATION |
|------------------|-----------|----------|--------------------|-----------------------------|
| -1.00 to -3.00 D | 2x        | 4x       | 3x                 | 2x                          |
| -3.00 to -6.00 D | 3x        | 4x       | 9x                 | 10x                         |
| Over -6.00 D     | 5x        | 14x      | 22x                | 41x                         |

Fleisch, D. J. "The complex interactions of retinal, optical and environmental factors in myopia aetiology." Progress in retinal and eye research 31:6 (2012): 622-660.

## RETINAL DETACHMENT




Each 1 D of myopia increases the incidence of retinal detachment by **30%**

Bullimore, Mark A., et al. "The risks and benefits of myopia control." Ophthalmology 128:11 (2021): 1501-1570.

## MYOPIC MACULAR DEGENERATION

| LEVEL OF MYOPIA  | CATARACTS | GLAUCOMA | RETINAL DETACHMENT | MYOPIC MACULAR DEGENERATION |
|------------------|-----------|----------|--------------------|-----------------------------|
| -1.00 to -3.00 D | 2x        | 4x       | 3x                 | 2x                          |
| -3.00 to -6.00 D | 3x        | 4x       | 9x                 | 10x                         |
| Over -6.00 D     | 5x        | 14x      | 22x                | 41x                         |


Fleisch, D. J. "The complex interactions of retinal, optical and environmental factors in myopia aetiology." Progress in retinal and eye research 31:6 (2012): 622-660.



1-diopter increase in myopia is associated with a **67% increase** in the prevalence of myopic maculopathy.

Bullimore, Mark A., and Noel A. Brennan. "Myopia control: why each diopter matters." Optometry and Vision Science 96:6 (2019): 463-465.  
Wong, Chee Wai, et al. "Is choroidal or scleral thickness related to myopic macular degeneration?" Investigative ophthalmology & visual science 58:2 (2017): 907-913.


## MYOPIC MACULAR DEGENERATION



- Stretched blood vessels
- Peripapillary atrophy
- Posterior staphyloma
- Lacquer cracks in Bruch's
- Geographic atrophy of RPE & choroid
- Subretinal hemorrhages
- Choroidal neovascularization

Bullimore, Mark A., and Noel A. Brennan. "Myopia control: why each diopter matters." Optometry and Vision Science 96:6 (2019): 463-465.  
Wong, Chee Wai, et al. "Is choroidal or scleral thickness related to myopic macular degeneration?" Investigative ophthalmology & visual science 58:2 (2017): 907-913.

MYOPIC MACULAR DEGENERATION




Wong, Chen Wai, et al. "Is choroidal or scleral thickness related to myopic macular degeneration?" Investigative ophthalmology & visual science 58.2 (2017): 907-913.



Bullimore, Mark A., et al. "The risks and benefits of myopia control." Ophthalmology 128.11 (2021): 1561-1570.

CHOROIDAL CHANGES



Choroidal Thickness in Myopic and Nonmyopic Children Assessed With Enhanced Depth Imaging Optical Coherence Tomography Invest. Ophthalmol. Vis. Sci. 2005;5:1023-1028. doi:10.1167/iovs.05.12722



"NUMBER NEEDED TO TREAT"


Table 7 Mean Lifetime Years of Visual Impairment as a Function of Level of Myopia Using the United States Definition of 20/40, Which Is the World Health Organization Definition of Mild Visual Impairment

| Myopia Level (D) | No. Needed to Treat to Prevent 5 Years of Visual Impairment |
|------------------|---|
| -3               | 6.75  |
| -4               | 5.97  |
| -5               | 5.35  |
| -6               | 4.85  |
| -7               | 4.44  |
| -8               | 4.11  |

D = diopter.  
Also shown are mean years of visual impairment prevented by a 1-D reduction in a patient's ultimate level of myopia, the number of patients needed to treat to prevent 5 years of visual impairment, and the reduction in myopia needed to prevent 1 year of visual impairment.

Bullimore, Mark A., et al. "The risks and benefits of myopia control." Ophthalmology 128.11 (2021): 1561-1570.

MYOPIC MACULAR DEGENERATION



"Slowing myopia by 1 diopter should reduce the likelihood of a patient developing myopic maculopathy by 40%.

Furthermore, this treatment **benefit accrues regardless of the level of myopia**. Thus, while the overall risk of myopic maculopathy is higher in a -6 diopter myope than in a -3 diopter myope, slowing their myopic progression by 1 diopter during childhood should lower the risk by 40% in both"

Bullimore, Mark A., and Noel A. Brennan. "Myopia control: why each diopter matters." Optometry and Vision Science 96.6 (2019): 463-465.

"NUMBER NEEDED TO TREAT"



EACH ADDITIONAL 1 D

**58%** increased risk of **MMD**

**20%** increased risk of **OAG**

**21%** increased risk of **PSC**

**30%** increased risk of **RD**

Bullimore, Mark A., et al. "The risks and benefits of myopia control." Ophthalmology 128.11 (2021): 1561-1570.





# Myopia


DISEASE OR REFRACTIVE ERROR?

2.1. **Physiological vs. pathological myopia**

The question whether myopia is merely an inconvenience or a 'disease' is often answered by dividing myopia into physiological myopia and pathological myopia (Curtin, 1985). Although this is a long-standing concept, it is still actively promoted by researchers in this field (e.g. Morgan et al., 2012). The cut-off between the two is conventionally, though arbitrarily, set at a spherical refractive equivalent of -6 Dioptres. Under this classification, **physiological myopia represents an inconvenience correctable by optical or surgical means and pathological myopia is a medical condition subject to the complications of extreme levels of myopia.** If this distinction was truly valid, low myopes would have no additional ocular disease risks over emmetropes. As the following analysis demonstrates significant disease associations exist even at low levels of myopia. Furthermore **there is no evidence of a safe threshold level of myopia for any of the known ocular diseases linked to myopia including myopic maculopathy.**

It is important to note that the following analysis addresses the potential disease associations of refractive errors. Low levels of myopia may certainly have some benefits in daily life, especially in later life after the onset of presbyopia (Rose and Tuohi, 1998). Furthermore, as is discussed below, physiological mechanisms may create myopia as a consequence of optically misguided emmetropization. Neither of these possibilities prevents myopia also having adverse consequences for ocular health, which is the fundamental reason for rejecting the concept of 'physiological myopia'.

Flitcroft, D. J. "The complex interactions of retinal, optical and environmental factors in myopia aetiology." *Progress in retinal and eye research* 31.6 (2012): 012-040.



## WCO Passes Resolution for Myopia Management Standard of Care

April 13, 2021

ST LOUIS — The World Council of Optometry (WCO) passed a resolution that encourages eye care professionals to adopt and follow a standard of care when treating myopia patients.

The resolution defines the evidence-based standard of care as having three main components:

- **Mitigation** — optometrists educating and counseling parents and children, during early and regular eye exams, on lifestyle, dietary, and other factors to prevent or delay the onset of myopia.
- **Measurement** — optometrists evaluating the status of a patient during regular comprehensive vision and eye health exams, such as measuring refractive error and axial length whenever possible.
- **Management** — optometrists addressing patients' needs of today by **correcting myopia**, while also providing evidence-based interventions (e.g., contact lenses, spectacles, pharmaceuticals) that **slow the progression of myopia, for improved quality of life and better eye health today and into the future.**

\*Myopia is increasing at an alarming rate, as are the risks for vision impairment associated with the condition\*. With more than five billion people projected to be affected by myopia by



## Risk Factors for Developing Myopia/High Myopia

## REFRACTIVE ERROR



"Refractive error is the best single predictor of future myopia – more powerful of a predictor than genetics, near work, and other risk factors."

- CLEERE Study

STATEMENT OF ENDORSEMENT Guidance for the Clinician in Rendering Pediatric Care

American Academy of Pediatrics  
DEDICATED TO THE HEALTH OF ALL CHILDREN™

## Reducing the Global Burden of Myopia by Delaying the Onset of Myopia and Reducing Myopic Progression in Children

The American Academy of Pediatrics has endorsed the following publication: Modjtahedi BS, Abbott RL, Fong DS, Lum F, Tan D; Task Force on Myopia. Reducing the global burden of myopia by delaying the onset of myopia and reducing myopic progression in children [published online ahead of print December 30, 2020]. *Ophthalmology*. doi:10.1016/j.ophtha.2020.10.040.

*All statements of endorsement from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.*

REFRACTIVE ERROR



REFRACTIVE ERROR

| Age  | Refractive Threshold for Risk of Myopia Development |
|------|---|
| 6    | < +0.75 D   |
| 7-8  | ≤ +0.50 D   |
| 9-10 | ≤ +0.25 D   |
| 11   | ≤ +0.00 D   |


REFRACTIVE ERROR

YOUNGER AGE OF MYOPIA ONSET = FASTER PROGRESSION

ONSET <10 YEARS, 26% BECOME HIGH MYOPES

ONSET >10 YEARS, 1% BECOME HIGH MYOPES

REFRACTIVE ERROR



Chua, et al. Ophthalmic Physiol Opt 2016.

REFRACTIVE ERROR

YOUNGER AGE OF MYOPIA ONSET = FASTER PROGRESSION

ONSET <10 YEARS, 26% BECOME HIGH MYOPES

ONSET >10 YEARS, 1% BECOME HIGH MYOPES


COMET STUDY: WHEN DOES MYOPIA STABILIZE? AGE OF 15, 18, OR 21?

50% 75% 90%

| Baseline Age (y) | Frequency of Progression of At Least -0.75D (%) | Frequency of Progression of At Least -1.00D (%) |
|------------------|---|---|
| 20 - 25          | 48.2 (40/83)                                    | 34.9 (29/83)                                    |
| 25 - 30          | 35.3 (36/102)                                   | 19.6 (20/102)                                   |
| 30 - 35          | 27.3 (18/66)                                    | 13.6 (9/66)                                     |
| 35 - 40          | 25.0 (10/40)                                    | 10.0 (4/40)                                     |
| Total            | 35.7 (104/291)                                  | 21.3 (62/291)                                   |

Bullimore, Mark A., et al. "A retrospective study of myopia progression in adult contact lens wearers." Investigative ophthalmology & visual science 43.7 (2002): 2110-2113.

GENETICS





## NEAR WORK



- **> 3 hours** of near work
- **Close** working distance
- 2% increased odds of myopia/  
**additional diopter-hour of time**  
spent on near work/ week
- **Continuous** > cumulative work
- **Digital devices**/Screen time.




- **> 3 hours** of near work
- **Close** working distance
- 2% increased odds of myopia/  
**additional diopter-hour of time**  
spent on near work/ week
- **Continuous** > cumulative work
- **Digital devices**/Screen time.

## NEAR WORK



## NEAR WORK


Huang HM, Chang DS, Wu PC. The Association between Near Work Activities and Myopia in Children-A Systematic Review and Meta-Analysis. PLoS One. 2015 Oct 20;10(10):e0140419







## OUTDOOR TIME



Gajjar, Shail, and Lisa A. Ostrin. "A systematic review of near work and myopia: measurement, relationships, mechanisms and clinical correlates." *Acta Ophthalmologica* 100.4 (2022): 376-387.



Lighthart, Gareth, et al. "How does spending time outdoors protect against myopia? A review." *British Journal of Ophthalmology* 104.5 (2020): 589-599.



## High accommodative lag: Potential feature + cause of myopia

- Pre-myopes show a higher accommodative lag compared to those who do not become myopic (1)
- Correlation becoming stronger after onset of myopia (2)

1. Mutti DO, Mitchell GL, Hayes JR et al. (CLEERE Study Group) Accommodative Lag before and after the Onset of Myopia. *Invest Ophthalmol Vis Sci* 2006;47:837-846.  
2. Mutti DO, Jones LA, Moeschberger ML, Zadnik K. AC/A Ratio, Age, and Refractive Error in Children. *Invest Ophthalmol Vis Sci* 2000;41:2469-2478.

## Esophoria & accommodative lag + lower than age-normal level of hyperopia (+0.75 or less at age 6-7 is the strongest risk factor for future myopia)<sup>1</sup>

- Recommend BV therapy + more time spent outdoors.<sup>2</sup>



## Intermittent exotropia (IXT)

- Associated with a higher prevalence of myopia
- 50% of children with IXT are myopic by age 10 and 90% are myopic by age 20.5



image cred: <https://geekymedics.com/strabismus/>

Eldawlati NS, Nuzat KI, Diehl NH, Mohney BG. The development of myopia among children with intermittent exotropia. *Am J Ophthalmol*. 2010 Mar;149(3):505-7.

## Esophoria


- Found to have more progressive myopia



image cred: <https://geekymedics.com/strabismus/>

Yang Z, Luo W, Ge J et al. The effectiveness of progressive addition lenses on the progression of myopia in Chinese children. *Ophthalmol Physiol Opt* 2009;29:41-48.

1. Zadnik K, Siveton LT, Carter SA, Jones Jordan LA, Kleinman RN, Mooney KE, Twilley JD, Mutti DO. Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study Group. Prediction of Juvenile-Onset Myopia. *JAMA Ophthalmol*. 2015 Jan;133(6):688-9.  
2. Xiong S, Stotland LG, Nishikuboki T, Zeng J, Guo Y, Zhu J, Li H, He X, Xu X. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. *Acta Ophthalmol*. 2017 Sep;95(6):551-564.




- ✓ Encourage outdoor time
- ✓ Discuss breaks from near work
- ✓ Perform cover test and assess for accommodative lag
- ✓ Start the discussion early
- ✓ Increase follow up frequency

- Recent study finding a combined prevalence of keratoconus or suspected keratoconus at approximately 1:223 (or 0.45%) in a U.S. school-aged population
- Average age of keratoconus or keratoconus suspects was 13.7 years old.

#### Screen for KTC

- Corneal topography/tomography
- Retinoscopy - scissoring reflex
- Keratometry- Normal values are below 48D, suspicious values are 48D to 50D and values above 50D are considered abnormally high

## Myopia Management Treatment Options & Prescribing Guide







Undercorrection



Undercorrection

Progression of spherical equivalent and axial length -Intent to treat model (Li et al 2013)




Adler D, Millodot M. The possible effect of undercorrection on myopia progression in children. Clin Exp Optom 2006; 88: 315- 321.  
Chung K, Mohidin N, O'Leary DJ. Undercorrection of myopia enhances rather than inhibits myopia progression. Vision Res 2002; 42: 2335- 2339.

Multifocals  
CANDIDATES

Refractive Error

- Monthly (center distance MF) SiHy:
  - Sphere: Up to -10.00 D
  - Cyl: Up to -5.75
- Monthly (center distance MF) Hydrogel:
  - Sphere: Up to -20.00 D
  - Cyl: Up to -5.75

Bifocals/Progressives




Multifocals  
CANDIDATES

Refractive Error


- Daily FDA-Approved (+2.00 Concentric Rings):
  - Sphere: Up to -7.00 D
  - Cyl: Up to -0.75
- Daily (aspheric center D):
  - Sphere: Up to -12.25 D

MULTIFOCALS

Multifocals  
MECHANISM



Multifocals  
EFFICACY




Walline JJ, Walker MK, Mutti DO, et al; for the BLINK Study Group. Effect of high add power, medium add power, or single-vision contact lenses on myopia progression in children: the BLINK randomized clinical trial. JAMA. Published August 11, 2020. doi:10.1001/jama.2020.10834

Multifocals  
EFFICACY


FDA APPROVAL RANGES

Age  
8-12 yo

Refraction  
-0.75 D to -4.00 D SE  
≤ 0.75 DC



Multifocals  
EFFICACY




Multifocals  
EFFICACY


**Design:**  
109 children (8-12 years old)  
-0.75 to -4.00D of myopia and < 1.00D of astigmatism

**Fit with either**  
MiSight 1-Day  
Proclear 1-Day

**Results (3 years):**  
-0.73 D (59%) reduction in myopia progression  
0.32 mm (52%) reduction in axial elongation  
No cases of serious ocular adverse events reported.




Multifocals  
EFFICACY



Chamberlain P et al. Myopia Progression in Children on Cessation of Dual-Focus Contact Lens Wear: MiSight 1-day 7-year findings AAO November 2021

Multifocals  
SAFETY



“ A daily disposable modality should be preferred ....solutions and storage cases are two major risk factors for infectious and inflammatory events ”

Chalmers, et al. Ophthalmic Physiol Opt. 2020.; Bullimore, et al. Ophthalmic Physiol Opt. 2020.

Multifocals  
SAFETY

“ Across the 6-years, there were no contact lens related serious adverse events and biomicroscopy showed no significant changes. Results suggest that children this age can successfully wear daily-disposable hydrogel contact lenses with minimal impact on ocular physiology. ”


Woods, Jill, et al. "Ocular health of children wearing daily disposable contact lenses over a 6-year period." Contact Lens and Anterior Eye 44.4 (2021): 101591.

Multifocals  
PRESCRIBING

Prescribing Multifocals:

- Cycloplegic, baseline refraction
- Quick BV evaluation
- Biometry
- Start or RTC for dispense + I&R

Multifocals  
SAFETY



ReCSS Study  
Retrospective Cohort Study of the Safety of  
Pediatric Soft Contact Lens Wear

- Studied children prescribed lenses <13 yo
- 1,000 children over 2,713 years of wear
- Annual incidence of inflammatory events: <1%
  - Conjunctivitis
  - FB abrasions
- No vision loss

Chalmers, et al. Ophthalmic Physiol Opt. 2020.; Bullimore, et al. Ophthalmic Physiol Opt. 2020.

Multifocals  
EXPECTATIONS

Potential for

- Haloes
- Over-refraction
- Increased dryness/allergies
- Initial I&R challenges

Chalmers, et al. Ophthalmic Physiol Opt. 2020.; Bullimore, et al. Ophthalmic Physiol Opt. 2020.

# ORTHOKERATOLOGY

## Orthokeratology

### CANDIDATES


#### Refractive Error

- Sphere: Up to -6.00D\*
- Cyl: Up to -1.75D\*


## Orthokeratology

### MECHANISM

#### BEFORE ORTHOKERATOLOGY TREATMENT




#### AFTER ORTHOKERATOLOGY TREATMENT



## Orthokeratology

### EFFICACY



"**Lens decentration** is a **common** phenomenon in orthokeratology. By excluding most of the interference factors, we found that OK lens being decentered less than 1.5 mm **can delay the development of myopia more effectively** than being centric"






Wang, A., & Yang, C. (2019). Influence of overnight orthokeratology lens treatment zone decentration on myopia progression. *Journal of Ophthalmology*, 2019.


## Orthokeratology

### MECHANISM



Vincent, Stephen J., et al. "BCLE CLEAR-Orthokeratology." *Contact Lens and Anterior Eye* 44.2 (2021): 240-249.






5 mm vs. 6 mm BOZD  
• 0.20 mm less AL

## Orthokeratology EFFICACY

### AXIAL ELONGATION

~50% Ranging from 41-45% in most meta-analyses.



## Orthokeratology SAFETY

“ The incidence of microbial keratitis was of 6.8 cases per 10,000 patient-years in adults and 0.0 cases per 10,000 patient-years in children...Corneal staining has been described as the most frequent adverse effect of ortho-k. ”

## Orthokeratology SAFETY

“ There is sufficient evidence to suggest that OrthoK is a safe option for myopia correction and retardation. Long-term success of OrthoK treatment requires a combination of proper lens fitting, rigorous compliance to lens care regimen, good adherence to routine follow-ups, and timely treatment of complications. ”

## Orthokeratology PRESCRIBING

### Prescribing Orthokeratology:

- Acuity sc and cc
- SLE with NaFl
- Cycloplegic, baseline refraction
- Quick BV evaluation
- Biometry
- Baseline Topography
- RTC for dispense + I&R

## Orthokeratology EXPECTATIONS

### Potential for

- Haloes
- Residual refraction (0.00 to +0.75)
- Increased dryness
- Initial I&R challenges
- Initial comfort issues
- Vision expectations

Liu, Yue M., and Peiyang Xie. "The safety of orthokeratology—a systematic review." Eye & contact lens 42.1 (2016): 55.


Weiss RS, Park S. Recent updates on myopia control: preventing progression. *J Disper at a time*. *Curr Opin Ophthalmol* 2018; 29: 224-30.  
Lipson M, Brooks M, Koffler B. The Role of Orthokeratology in Myopia Control: A Review. *Eye Contact Lens* 2018; 44: 224-30.  
Chung SW, Boast MW, Cho P. Pre-treatment observation of axial elongation for evidence-based selection of children in Hong Kong for myopia control. *Contact Lens Anterior Eye* 2018; 42: 224-30.  
Hirooka T, Kohno T, Okamoto F, Takahashi H, Oshika T. Long-term effect of overnight orthokeratology on axial length elongation in childhood myopia: a 5-year follow-up study. *Invest Ophthalmol Vis Sci* 2012; 53: 1813-7.  
Swanwick HA, Alharbi A, Watt G, Lam S, Kong P. Myopia control during orthokeratology lens wear in children using a novel study design. *Ophthalmology* 2015; 122: 200-10.

Giispets, Joan, et al. "Efficacy, predictability and safety of long-term orthokeratology: An 18-year follow-up study." *Contact Lens and Anterior Eye* 45.1 (2022).



**PDCL:** MiSight, Biofinity, Proclear, SpecialEyes Multifocal, NaturalVue  
**OK:** Corneal Reshaping Therapy, Vision Shaping Treatment

Skidmore, Kelsea V., et al. "Retrospective review of the effectiveness of orthokeratology versus soft peripheral defocus contact lenses for myopia management in an academic setting." *Ophthalmic and Physiological Optics* 43.3 (2023): 534-543.



## Consider

- 



## ATROPINE



1. Gifford K, Gifford P, Hendicott PL, Schmid LK. Binocular visual function in young adult orthokeratology versus soft contact lens wearers. *Cont Lens Anterior Eye*. 2017 Jun;40(4):184-189.
2. Gifford K, Gifford P, Hendicott PL, Schmid LK. Zone of Clear Single Binocular Vision in Myopic Orthokeratology. *Eye Contact Lens*. 2020 Mar;46(2):82-90.
3. Schmid LK, Gifford K, Gifford P, Hendicott PL, Schmid LK. Assessing Multifocal Lenses for Myopia Control. *Optom*. 2019 Jun;100(6):44-51.
4. Schmid LK, Gifford K, Chan P, Christie B, Crouther S, Nahayson O, Sachnevna K, Sevil L, Youssef M, Atchison DA. The effects of aspheric and concentric multifocal soft contact lenses on visual quality, vergence and accommodation in young adult myopes. *Invest Ophthalmol Vis Sci*. 2019 Jun;60(10):3893.
5. Schmid LK, Gifford K, Chan P, Christie B, Crouther S, Nahayson O, Sachnevna K, Sevil L, Youssef M, Atchison DA. The effects of aspheric and concentric multifocal soft contact lenses on visual quality, vergence and accommodation in young adult myopes wearing multifocal lenses. *Invest Ophthalmol Vis Sci*. 2019 Jun;60(10):3893.
6. Riva S, Gifford K, Pérez-Sánchez B, Calhades P, Prieto-García R, Gutierrez-Ortega R, Villa-Cañal C. Binocular and accommodative function of the visual midline. *Optom*. 2019 Jun;100(6):44-51.
7. Assessment Study Panel (MAGS). *Gaillard Expt Opt*. Gifford P, Chan P, Christie B, Crouther S, Nahayson O, Sachnevna K, Sevil L, Youssef M, Atchison DA. The effects of aspheric and concentric multifocal soft contact lenses on visual quality, vergence and accommodation in young adult myopes wearing multifocal lenses. *Invest Ophthalmol Vis Sci*. 2019 Jun;60(10):3893.




## Atropine CANDIDATES

### Refractive Error

- No Limit!

## Atropine EFFICACY



## Atropine MECHANISM


Non-selective antagonist of muscarinic acetylcholine receptors

Muscarinic ACh Receptors are found in the:

**Retina:** The layer involved in transferring the signaling cascade toward the choroid and/or the sclera. Atropine boosts dopamine release from cellular stores, which then controls eye growth.

**Choroid:** Atropine results in rapid and transient choroidal thickening and inhibited eye growth. Suggested that the choroidal thickening and eye growth may be linked. Atropine was found to inhibit choroidal thinning induced by hyperopic defocus.

**Sclera:** Blocks the proliferation of scleral fibroblasts and consequent axial elongation



## Atropine EFFICACY - ATOM 2


### Design

Randomized into groups:

- 0.5%
- 0.1%
- 0.01%

### Goal

Compare safety and efficacy of lower doses of atropine




## Atropine EFFICACY - ATOM 1

### Design


- 400 myopic children (6-12 yo)
- SE -1.00 to -6.00D
- 1% atropine or saline drops
- 1 gtt qd x 2 years

### Results


- 80% reduction



## Atropine EFFICACY



Atropine  
EFFICACY



Atropine  
EFFICACY

0.05% atropine remained the optimal concentration over 3 years

The difference in rebound effects were clinically small across all three studied atropine concentrations.

Stopping treatment at an older age was associated with a smaller rebound.

Atropine  
EFFICACY - LAMP


**Design**

383 myopic children (4-12 yo)  $\geq -1.00$  D

Randomized into groups:

- 0.05%
- 0.025%
- 0.01%
- Placebo

1 gtt qd x 2 years



Atropine  
EFFICACY

|                       | ATOM 2 |      |       | LAMP  |        |       |
|-----------------------|--------|------|-------|-------|--------|-------|
| Atropine Dosage       | 0.5%   | 0.1% | 0.01% | 0.05% | 0.025% | 0.01% |
| Refractive Efficiency | 75%    | 68%  | 59%   | 66%   | 43%    | 27%   |
| Axial Efficiency      | 29%    | 25%  | -8%   | 51%   | 29%    | 12%   |

Atropine  
EFFICACY


**Design**

383 myopic children (4-12 yo)  $\geq -1.00$  D

Randomized into groups:

- 0.05%
- 0.025%
- 0.01%
- Placebo

1 gtt qd x 2 years



What's in a Bottle

A Survey of 26 pharmacies across 19 US states

- Diluted from 1% atropine gtts or atropine powder
- Preservatives may vary: BAK commonly used
- Atropine is an unstable compound
  - Susceptible to hydrolysis - influenced by pH and carriers/preservatives/diluting agents
  - Analysis found the actual concentration compared to the prescribed concentration was:
    - As low as 70% and a quarter of all samples were under the 90% minimum target concentration.
    - More neutral pH = more degradation

What’s in a Bottle?

**Variability in compounding** may be why some studies report minimal side effects while other studies report problems with photophobia and accommodation.

**Most common side effect of low-concentration atropine is allergic conjunctivitis**

- Independent of concentration
- Occurred in placebo groups



Questions to Ask Your Pharmacy



- Shelf Life
- Preservatives Used
- Refrigerated or room-temp
- Frequency of testing concentrations



Richdale K, Tomiyama ES, Newack GD, Bullimore MA. Compounding of Low-Concentration Atropine for Myopia Control. Eye Contact Lens 2022;48:489-92.  
Watson CJ, Whitley JD, Sani AA, Burns MM. Pharmaceutical Compounding: a History, Regulatory Overview, and Systematic Review of Compounding Errors. J Med Toxicol 2021;37:217-231.  
Yan J-C, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology 2019;126:113-24.

Richdale K, Tomiyama ES, Newack GD, Bullimore MA. Compounding of Low-Concentration Atropine for Myopia Control. Eye Contact Lens 2022;48:489-92.  
Watson CJ, Whitley JD, Sani AA, Burns MM. Pharmaceutical Compounding: a History, Regulatory Overview, and Systematic Review of Compounding Errors. J Med Toxicol 2021;37:217-231.  
Yan J-C, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Ophthalmology 2019;126:113-24.


Atropine  
EXPECTATIONS


- Potential for
- Light sensitivity
  - Initial burning
  - Near vision blur
  - Increased pupil size


Atropine  
PRESCRIBING















- Prescribing Atropine:
- Cycloplegic, baseline refraction
  - Quick BV evaluation
  - Biometry
  - Pupillometry - Size and Response
  - Atropine 0.05%: 1 gtt OU qhs
  - Consider visual fatigue lenses w. photochromic lenses

|                             | 0.05% Atropine | 0.025% Atropine | 0.01% Atropine | Placebo |
|-----------------------------|----------------|-----------------|----------------|---------|
| Photopic pupil size (+mm)   | 1.03           | 0.76            | 0.80           | 0.13    |
| Photophobia, 2 weeks        | 31.2%          | 18.5%           | 5.5%           | 12.6%   |
| Photophobia, 1 year         | 7.8%           | 6.6%            | 2.1%           | 4.3%    |
| Photochromic Lenses         | 30.3%          | 34.3%           | 30%            | 39.6%   |
| Accommodative Amp (D), 4 mo | -2.38          | -1.34           | -0.50          | -0.35   |
| Accommodative Amp (D), 1 yr | -1.98          | -1.61           | -0.26          | -0.32   |
| PALS                        | 0.96%          | 0%              | 1.8%           | 0.9%    |

**Follow-up Schedules**

These are the recommended minimum follow-up intervals from the International Myopia Institute (IMI) Clinical Management Guidelines.

Copyright © 2019-2023 Myopia Profile Pty Ltd All Rights Reserved. Scan to learn more

| 1 Day   | 4-7 Days  | 1 Month   | 3 Months  | 6 Monthly   |
|---|---|---|---|---|
|   |   |    |   |    |
| Soft Contact Lenses   |   |   |   |   |
|   |  |  |   |  |
| Ortho-k   |   |   |   |   |
|  |  |  |  |  |
| Atropine  |   |   |   |   |
|   |  |  |  |  |



| ATROPINE | MULTIFOCAL CLS | ORTHOKERATOLOGY |
|----------|----------------|-----------------|
|----------|----------------|-----------------|

|                      |                   |                        |
|----------------------|-------------------|------------------------|
| Visual Acuity        |                   |                        |
| Biometry             | + Over-refraction | + Slit Lamp (w. stain) |
| Refraction           |                   | with & without lenses  |
| Slit Lamp (w. stain) |                   |                        |

| ATROPINE | MULTIFOCAL CLS | ORTHOKERATOLOGY |
|----------|----------------|-----------------|
|----------|----------------|-----------------|

|                      |                   |                        |
|----------------------|-------------------|------------------------|
| Visual Acuity        |                   |                        |
| Biometry             | + Over-refraction | + Slit Lamp (w. stain) |
| Refraction           |                   | with & without lenses  |
| Slit Lamp (w. stain) |                   |                        |

| ATROPINE | MULTIFOCAL CLS | ORTHOKERATOLOGY |
|----------|----------------|-----------------|
|----------|----------------|-----------------|

|                      |                   |                        |
|----------------------|-------------------|------------------------|
| Visual Acuity        |                   |                        |
| Biometry             | + Over-refraction | + Slit Lamp (w. stain) |
| Refraction           |                   | with & without lenses  |
| Slit Lamp (w. stain) |                   |                        |

## FOLLOW UP PROTOCOL

- 
- **Aggressive Myopia**
    - High risk factors - young age, genetics, previous progression
    - Growth spurt
    - Winter months
  - **Non-compliance**
    - A: burns?
    - MF CLs: Time in AM?
  - **User Error**
    - A: Not instilling correctly
    - OK: Not wearing long enough




**Figure 1: Annual change in axial eye length**

The figure illustrates the annual change in axial eye length for different myopia types. The bar chart shows the following data:


| Myopia Type   | Annual Change in Axial Eye Length (mm)                |
|---|---|
| Stellate™ MYOSMART™, MSight™, Ortho-K, Atropine 0.05%                         | -0.50D (9 yrs), -0.37D (9-11 yrs), -0.25D (12-16 yrs) |
| Bifocal and prism blocked glasses, Mylo™, BliQnity™ CD +2.5D, Atropine 0.025% | -0.67D (9 yrs), -0.50D (9-11 yrs), -0.37D (12-16 yrs) |
| Progressive / Multifocal glasses, Atropine 0.01%                              | -0.75D (9 yrs), -0.67D (9-11 yrs), -0.37D (12-16 yrs) |
| Single Vision: Unchecked average progression                                  | -1.00D (9 yrs), -0.75D (9-11 yrs), -0.50D (12-16 yrs) |

The diagram shows a myopic eye with an axial length of 24.0mm. The timeline indicates that a myopia showing axial length change similar to the emmetropes rate is likely showing a good myopia control outcome.




## 4. Gauging Success


The charts below show average refractive progression per year, based on child's age and current myopia control intervention. Faster-than-average progression may be due to compliance issues or individual factors.



Copyright © 2019-2023  
Myopia Profile Pty Ltd All Rights Reserved


[Scan to learn more](#)






## 4. Gauging Success


The charts below show average refractive progression per year, based on child's age and current myopia control intervention. Faster-than-average progression may be due to compliance issues or individual factors.



Copyright © 2019-2023  
Myopia Profile Pty Ltd All Rights Reserved


[Scan to learn more](#)






## 4. Gauging Success


The charts below show average refractive progression per year, based on child's age and current myopia control intervention. Faster-than-average progression may be due to compliance issues or individual factors.



Copyright © 2019-2023  
Myopia Profile Pty Ltd All Rights Reserved

[Scan to learn more](#)





on?

**NOW WUT?**

- ✓ **Consider all risk factors**
- ✓ **Increase ttx**
  - Higher add
  - Increase atropin
  - Change ortho-k
- ✓ **Add combination t**
- ✓ **Switch modalities**

- 
- on?
- NOW WUT?**
- ✓ Consider all risk factors
  - ✓ Increase ttx
    - Higher add
    - Increase atropin
    - Change ortho-k
  - ✓ Add combination t
  - ✓ Switch modalities




- 
- on?
- NOW WUT?**
- ✓ Consider all risk factors
  - ✓ Increase ttx
    - Higher add
    - Increase atropin
    - Change ortho-k
  - ✓ Add combination t
  - ✓ Switch modalities

On the Horizon  
SPECTACLES

| Treatment Effect in Slowing Myopia Progression over the Study Period (compared to single vision lenses as control) |                 |                                      |  |
|--|-----------------|--------------------------------------|--|
| Study  | Period (months) | Mean Adjusted Difference in Diopters | Mean Adjusted Difference in mm of Axial Length |
| <b>Meta-analysis (10)</b>  |                 |                                      |  |
| Lam et al. (2020)(11)  | 12              | -0.37 (0.4%)                         | -0.22 (0.1%)                                   |
| Lam et al. (2020)(11)  | 24              | -0.44 (0.2%)                         | -0.34 (0.0%)                                   |
| <b>Random (94.1)</b>   |                 |                                      |  |
| Best et al. (2021)(16)   | 12              | -0.50 (0.0%)                         | -0.22 (0.0%)                                   |
| Best et al. (2021)(16)   | 24              | -0.37 (0.0%)                         | -0.34 (0.0%)                                   |
| <b>Fixed-effects (99.7)</b>  |                 |                                      |  |
| Rapin et al. (2022)(2)   | 24              | -0.52 (1%)                           | -0.21 (1%)                                     |

\*Random data presented at ARVO 2022  
\*Statistical analysis method not disclosed. Percentage value not disclosed. Subjects who removed test spectacles for near tasks were excluded from this analysis

reviewofmms.com/myopia-control-with-innovative-spectacle-lenses/



On the Horizon: RED LIGHT THERAPY

**Repeated Low-Level Red-Light Therapy: Critical Questions Remain**

December 1, 2023

By Daiguo Korman, MD, MBA, PhD, FRCPC, FRCPC

**Repeated low-level red-light therapy (RLRL)** is a novel and promising intervention for myopia management. RLRL involves exposing the retina of a child to red light at a wavelength between 650–670 nanometers, twice daily for three months, after first hours in darkness and fast to avoid heat stress. RLRL is available in several markets worldwide, but it is not fully approved or available in the United States.

Robison et al. have written a comprehensive overview of the current evidence for utilizing RLRL to treat pediatric myopia. The authors review the current evidence on the safety and efficacy of red light as a myopia control intervention, describe potential mechanisms, and discuss some key unanswered issues that require consideration before red light can be broadly translated into myopia control in children.

Repeating exposures combined with sleep have been postulated as the efficacy of red light to increase dopamine in children. These authors discuss and recommend that such data

**Low-Level Red Light Therapy: Safety Concerns Continue**

February 15, 2024

By Daiguo Korman, MD, MBA, PhD, FRCPC, FRCPC

**Photochromic (photochromic) lenses**


The use of **low-level red light (LLRL)** therapy has gained popularity as a treatment for myopia in children. However, concerns have been raised about the safety of these devices, as their output may exceed the recommended safety limits. A recent study conducted by Carl Cohen and Alexander Tsai aimed to investigate the output of three LLRL devices and determine their thermal and photochemical exposure permissible exposure (PE) for myopia control.

The study examined two LLRL devices – the Sky 1000 and the Future Vision – and measured their optical power using an integrating sphere radiometer through a 7-mm diameter aperture. The spectral output of the devices were obtained using a spectrometer and high-resolution beam profile. The thermal exposure, retinal irradiance, and MPE were then

TALKING TO PARENTS



On the Horizon: RED LIGHT THERAPY



Develop a Script







## Focus on Emotion vs Scare Tactics

“  
Glaucoma  
Cataracts

Myopic  
Macular  
Degeneration



## Use Examples that Resonate



## Provide Resources



Brochures



Email



MM Specialty Tech

1. Visual Environment Advice

- At least 2 hours a day outdoors
- The two hour rule
- Elbow rule
- 20/20 rule

2. What Are My Options?

- Best
- Next-best
- Less effective
- Not effective

3. Kids Can Wear Contact Lenses

- They're safe for children
- Low risk of infection
- Improves self-confidence
- Quick to learn how to use

4. Why Management is Essential

- Short-term Goal
- Long-term Goal
- Contact (PMMA)
- Retinal Detachment
- Myopic Maculopathy

## Give Homework Before I&R

MY KIDS VISION

Soft contact lens application and removal

- SOFT CONTACT LENSES
- SOFT CONTACT LENSES
- SOFT CONTACT LENSES

Orthokeratology lens application and removal

- ORTHOK LENSES
- ORTHOK LENSES
- ORTHOK LENSES



The Importance of  
Myopia Management


Myopia Management  
Treatment Options &  
Prescribing Guide

Risk Factors for  
Developing  
Myopia/High Myopia

THANK  
YOU!



Ariel Cerenzie, OD, FSLs, FAAO  
drc@charlottecontactlens.com



| • 8 months: 20 minutes  |  | • 8 months: 20 minutes   |  |
|---|--|--|--|
| Total: 2,167 Hours<br>Desired Gross Revenue: 2,167 x \$360                              |  | Total: 1,85 Hours<br>Desired Gross Revenue: 2,167 x \$360  |  |
| \$780 MINIMUM   |  | \$650 MINIMUM  |  |
| Courtesy of Dr. Ariel Cerenzie  |  |  |  |
| Setting Your Fees<br>REVENUE PER OD HOUR  |  | I  |  |
| Orthokeratology<br>• \$1,020 for visits<br>• \$600 for materials<br>Total/Year: \$1,620 |  | FDA Approved Myopia Control CL<br>• \$1,020 for visits<br>• \$1,000 for materials<br>Total/Year: \$2,020 |  |
| Courtesy of Dr. Ariel Cerenzie  |  |  |  |



Setting Your Fees